Latest Consumer Health News

Doctor Care Anywhere has snapped up the GLP-1 and medicated weight-loss business of Outcome Diagnostics and MedicSpot for £850,000, adding £5.3 million in trailing revenue and expanding its direct-to-consumer footprint in the UK.

Starpharma has confirmed FDA alignment for its DEP® HER2 first-in-human phase 1 trial, with preparations underway for a mid-2026 start. The biotech also progressed strategic partnerships, published promising data with Genentech, and reported a $14.1 million cash balance alongside rising Viraleze™ sales.

Global Health Ltd reports stable revenue and a significant EBITDA improvement in H1 FY26, driven by a strategic shift to SaaS platforms and AI integration. The company’s partnership with Best Practice and upcoming Lifecard launch position it for growth in Australia’s digital healthcare sector.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

EZZ Life Science Holdings has secured a four-year exclusive global distribution agreement with Aumake Limited, committing to at least A$10 million in purchases. This partnership aims to accelerate EZZ’s international reach while preserving brand control.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Wellnex Life reports encouraging early results from its turnaround strategy, posting a modest EBITDA profit and robust sales growth for its Pain Away brand.

CONNEQT Health’s Pulse arterial health monitor sales have outpaced expectations with over 200% growth in the December quarter, driven by efficient marketing and early subscription uptake.

EZZ Life Science Holdings reported a 25% drop in Q1 receipts, driven by seasonal softness and campaign timing, while accelerating its US market entry and launching three new health supplements.

CONNEQT Health reports robust 50% quarter-on-quarter growth in Pulse device sales and launches a new pricing strategy to boost recurring revenue. The company also secures a significant US clinical trial contract and advances cost-cutting efforts.

Bioxyne Limited projects FY2026 revenue between $65 million and $75 million, driven by expansion in Australian medical cannabis and a landmark $5.8 million contract in Germany.